Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of bifidobacterium breve CCFM1025 in relieving Alzheimer's disease

A technology of CCFM1025 and Bifidobacterium breve, which is applied in the field of microbiology, can solve the problems of complex research methods of intestinal flora, few clinical studies of intestinal flora, and lack of types of spiritual probiotics, etc., so as to increase the relative abundance and improve Cognitive impairment, content-enhancing effect

Active Publication Date: 2021-06-18
JIANGNAN UNIV
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the types of "mental probiotics" that are known to be used to prevent and treat neurological diseases are too scarce; secondly, due to the complexity of the intestinal flora and the difficulty of research methods, there are few clinical studies on the intestinal flora, and their participation The mechanism of body metabolism and interaction has not been clarified; therefore, it is very important to screen out a probiotic that can mediate intestinal flora to relieve Alzheimer's disease, dig into its function, and develop probiotic products with higher health value. important

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of bifidobacterium breve CCFM1025 in relieving Alzheimer's disease
  • Application of bifidobacterium breve CCFM1025 in relieving Alzheimer's disease
  • Application of bifidobacterium breve CCFM1025 in relieving Alzheimer's disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Example 1: Bifidobacterium breve CCFM1025 improves the behavioral indicators of Alzheimer's disease mice

[0043] Thirty-two 7-week-old male C57BL / 6J mice were taken, and after one week of adaptation to the environment, Aβ1-42 protein was microinjected into the brain hippocampus at one time to establish an animal model of Alzheimer's disease. On the third day after the model was established, the animals were divided into Four groups: control group (injection of equal volume of normal saline), model group, drug intervention group, and CCFM1025 intervention group, with 8 mice in each group. The animal groups and treatment methods are shown in Table 1.

[0044] Table 1 Grouping and processing methods of animal experiments

[0045]

[0046]

[0047] AD mouse model induced by microinjection of Aβ1-42 protein in the brain: After the mice were adapted for one week, the mice in each group were anesthetized with isoflurane (induction concentration 3%, maintenance concentr...

Embodiment 2

[0060] Example 2: CCFM1025 reduces Aβ protein deposition in the brains of Alzheimer's mice

[0061] The mouse grouping, modeling and treatment methods were the same as in Example 1. After the mouse behavior experiment, the next day, the mice were injected intraperitoneally with 1% pentobarbital sodium solution to make them anesthetized, and the mice were killed. The brain tissue of the mice was taken and separated on ice. Hippocampus. Take a certain quality of fresh hippocampus tissue, add 9 times the volume of sterile PBS buffer solution (equivalent to 1g tissue plus 9ml homogenate), homogenize with a tissue homogenizer, and take the supernatant after the tissue fluid is centrifuged at 3000g for 15min. The content of β-amyloid protein (Aβ1-42) in hippocampus was detected by ELISA kit.

[0062] Experimental results such as Figure 4 As shown, the results show that the intervention of Bifidobacterium breve CCFM1025 can significantly reduce the deposition of Aβ1-42 protein in...

Embodiment 3

[0063] Example 3: Bifidobacterium breve CCFM1025 increases the levels of neurotransmitters and synaptic proteins in the brains of Alzheimer's mice

[0064] Take a certain amount of brain tissue obtained in Example 2, add 9 times the volume of sterile PBS buffer (equivalent to 1g of tissue plus 9ml of homogenate), homogenize with a tissue homogenizer, and take the tissue fluid after centrifugation at 3000g and 15min. In the supernatant, ELISA kit was used to detect the content of brain-derived neurotrophic factor BDNF in the brain tissue.

[0065] Experimental results such as Figure 5 As shown in A, the results showed that the intervention of Bifidobacterium breve CCFM1025 significantly reversed the reduction of BDNF levels in the brains of Alzheimer's disease model mice, and restored the BDNF content from 143.66pg / mL in the model group to 172.55pg / mL, compared with The content of the control group was the same, and the improvement effect of CCFM1025 on BDNF in the brain was ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of bifidobacterium breve CCFM1025 in relieving Alzheimer's disease, and belongs to the field of microorganisms. The bifidobacterium breve CCFM1025 can significantly improve cognitive and memory disorder of mice with Alzheimer's disease, reduce the content of A beta 1-42 protein in the brains of the mice with Alzheimer's disease, improve the level of brain-derived neurotrophic factors and postsynaptic density protein in the brains of the mice with Alzheimer's disease, and improve the content of interleukin 6 in the serum of the mice with Alzheimer's disease; and the bifidobacterium breve CCFM1025 can regulate intestinal flora and metabolites thereof. The bifidobacterium breve CCFM1025 can be used for preparing pharmaceutical compositions for relieving dementia and Alzheimer's disease and improving cognitive disorder, can also be used as a microecological preparation to be applied to drugs, fermented food or health care products, and has a very wide application prospect.

Description

technical field [0001] The invention relates to the application of Bifidobacterium breve CCFM1025 in alleviating Alzheimer's disease, and belongs to the technical field of microorganisms. Background technique [0002] Alzheimer's disease, also known as senile dementia, is a neurodegenerative disease, clinically manifested as a decline in learning and cognitive ability, and a gradual loss of self-care ability. The clinical characteristics of Alzheimer's disease are insidious onset, progressive aggravation, and death due to complications within 10-20 years of onset. Alzheimer's disease accounts for 60-80% of all dementia patients and is the most common type of dementia. [0003] Regarding the pathogenesis of Alzheimer's disease, there are currently more than a dozen hypotheses in modern medicine, and the most studied are the theory of cholinergic loss, the theory of hyperphosphorylation of Tau protein, the theory of oxidative stress, the theory of β-amyloid toxicity, Inflamm...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/745A23L33/135A23L11/50A23C9/123A23C13/16A23C19/00A61P25/28A61P1/00
CPCA61K35/745A61P25/28A61P1/00A23L33/135A23C9/1234A23C13/16A23C19/00A23V2002/00A23V2400/519A23V2200/322A23V2200/3204
Inventor 王刚朱广素陈卫赵建新张灏
Owner JIANGNAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com